Johnson & Johnson $JNJ Shares Bought by Leuthold Group LLC

Leuthold Group LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 9.5% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 34,031 shares of the company’s stock after acquiring an additional 2,946 shares during the period. Leuthold Group LLC’s holdings in Johnson & Johnson were worth $9,009,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in JNJ. Outlook Capital Management LLC bought a new stake in shares of Johnson & Johnson during the 2nd quarter valued at about $28,000. Navigoe LLC grew its holdings in shares of Johnson & Johnson by 60.4% during the third quarter. Navigoe LLC now owns 146 shares of the company’s stock worth $38,000 after purchasing an additional 55 shares in the last quarter. Matrix Trust Co grew its holdings in shares of Johnson & Johnson by 56.2% during the second quarter. Matrix Trust Co now owns 150 shares of the company’s stock worth $38,000 after purchasing an additional 54 shares in the last quarter. Montgomery Financial Services LLC purchased a new stake in Johnson & Johnson in the second quarter valued at approximately $43,000. Finally, Hanseatic Management Services Inc. purchased a new stake in Johnson & Johnson in the third quarter valued at approximately $52,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: In a first-in-human Phase 1 study, the investigational pasritamig–JNJ-9401 combination produced a PSA reduction of at least 50% in 11 of 15 patients with advanced prostate cancer; nearly half had reductions of at least 90%. J&J reported an encouraging safety profile and said the regimen is advancing toward Phase 3, though the small early-stage study carries substantial uncertainty. Article: Johnson & Johnson reports 73% PSA response rate
• Positive Sentiment: ICOTYDE (icotrokinra) met the primary endpoint in a Phase 3 trial in biologic-naive patients with psoriatic arthritis, supporting the potential of this once-daily oral treatment. Article: ICOTYDE meets primary endpoint in Phase 3 study
• Positive Sentiment: J&J also presented new nipocalimab data in Sjögren’s disease and reported positive results for autoimmune therapies at a medical meeting, adding to the pipeline’s potential, although the reports provide limited detail on commercial impact. Article: New Phase 2 nipocalimab study data
• Negative Sentiment: ETF investors were net sellers of J&J shares on Nov. 5, a modestly negative flow signal that predates the latest trial announcements. Article: ETFs are net sellers of Johnson & Johnson

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares in the company, valued at approximately $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Jennifer L. Taubert sold 15,000 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the sale, the executive vice president directly owned 194,451 shares of the company’s stock, valued at approximately $51,210,615.36. This trade represents a 7.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $281.86 on Tuesday. The firm has a fifty day simple moving average of $266.18 and a two-hundred day simple moving average of $248.62. Johnson & Johnson has a twelve month low of $185.12 and a twelve month high of $282.73. The company has a market capitalization of $678.53 billion, a PE ratio of 42.71, a P/E/G ratio of 2.73 and a beta of 0.22. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The firm had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. During the same quarter in the previous year, the business earned $2.80 earnings per share. The company’s quarterly revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Research analysts expect that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be given a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 1.9%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 81.21%.

Analysts Set New Price Targets

A number of equities analysts have commented on JNJ shares. Bank of America reissued a “neutral” rating and issued a $278.00 price target on shares of Johnson & Johnson in a research note on Tuesday, September 29th. Morgan Stanley lowered their price objective on shares of Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating on the stock in a research report on Thursday, October 15th. UBS Group set a $270.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 14th. Evercore set a $300.00 target price on shares of Johnson & Johnson in a research report on Tuesday, October 20th. Finally, Erste Group Bank cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, October 21st. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $275.92.

Johnson & Johnson Company Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech.

Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care.

Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.